AbbVie (ABBV) Stock May Be 41% Undervalued Following JUVMO Approval

AbbVie has delivered a powerful 187.5% total return over the past 5 years, so the current US$261.59 share price naturally raises a question for investors who care about cash generation. With fresh drug approvals, pipeline updates and new partnerships in the headlines, the key issue now is whether AbbVie’s cash flows are strong enough and durable enough to underpin where the stock trades today. That 187.5% 5 year return puts real pressure on the valuation question, because a move of that size...